drugset
drugset / Trial / NCT06553287

Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.

NCT06553287 ↗

Phase 1 Completed 28 enrolled Lynk Pharmaceuticals Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the Safety, Tolerability, and Pharmacokinetics of LNK01004 ointment (0.3%, 1.0%, and 1.5%) vs vehicle twice daily (BID) in Adults Patients with Atopic Dermatitis.

Timeline

Start
2023-07-12
Primary completion
2024-06-18
Completion
2024-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject LNK01004 Unknown 0.3 % Topical
Subject LNK01004 Unknown 1 % Topical
Subject LNK01004 Unknown 1.5 % Topical

Indications

atopic eczema